Clinical Trials Logo
  1. Home
  2. Neoplasms Pancreatic
  3. NCT04176952

PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer — PRIMUS002  

Neoplasms Pancreatic Clinical Trial

Official title:
PRIMUS002: An Umbrella Phase II Study Examining Two Neo-adjuvant Regimens (FOLFOX-A and AG) in Resectable and Borderline Resectable Pancreatic Ductal AdenoCarcinoma (PDAC), Focusing on Biomarker and Liquid Biopsy Development

Clinical Trial Summary

PRIMUS 002 is looking at 2 different chemotherapy regimens in the neo-adjuvant setting for pancreatic cancer. Each treatment will be given for 3 months prior to surgery

Clinical Trial Description

This is an integrated, open label, non-randomised, phase II trial of 2 neo-adjuvant regimens (FOLFOX-A and AG) assessing efficacy and toxicity with integrated translational work. The study is powered on testing a proposed DNA damage response deficient biomarker for responsiveness in patients treated with FOLFOX-A; patients being treated with AG are recruited concurrently. The study has a prospective safety assessment of neo-adjuvant chemotherapy and neo-adjuvant chemotherapy followed by chemoradiotherapy consisting of conventional radiotherapy with concomitant capecitabine. This safety assessment will include all patients (FOLFOX-A and AG) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04176952
Study type Interventional
Source University of Glasgow
Contact
Status Terminated
Phase Phase 2
Start date March 5, 2019
Completion date August 19, 2021
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01313416 - Gemcitabine and CT-011 for Resected Pancreatic Cancer Phase 2
Completed NCT05547074 - A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma
Withdrawn NCT03245658 - The Effect of Cannabis in Pancreatic Cancer Phase 2
Completed NCT02973217 - Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer N/A
Recruiting NCT04151277 - PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer Phase 2
Recruiting NCT04161417 - Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer N/A
Terminated NCT03187587 - Percutaneous Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer N/A
Recruiting NCT05669482 - Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer Phase 1/Phase 2
Completed NCT03535727 - A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT04566614 - Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies
Completed NCT06118125 - Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confinement
Active, not recruiting NCT03678883 - 9-ING-41 in Patients With Advanced Cancers Phase 2